Telix Posts 22% Revenue Growth, Advances Key Radiopharmaceutical Trials
Event summary
- Telix reported H1 2026 revenue of US$477 million, up 22% YoY, tracking toward US$950–970 million full-year guidance.
- Precision Medicine segment revenue grew 27% YoY, driven by Illuccix® and Gozellix® volume growth.
- Adjusted EBITDA surged 146% YoY to US$52 million, boosted by a US$40 million Regeneron collaboration payment.
- TLX591-Tx (ProstACT Global) and TLX101-Tx (IPAX BrIGHT) advanced in pivotal trials for prostate cancer and glioblastoma.
- Company issued US$600 million in convertible bonds due 2031 and established an ATM facility for share issuance.
The big picture
Telix’s strong H1 2026 performance reflects growing demand for its precision medicine portfolio and strategic bets on radiopharmaceutical therapeutics. The company’s ability to scale manufacturing and secure regulatory approvals will determine its position in the rapidly evolving oncology theranostics market. With US$40 million from Regeneron and a US$600 million refinancing, Telix is positioning itself for long-term growth, but execution risks remain in its late-stage pipeline.
What we're watching
- Regulatory Milestones
- Whether FDA and NMPA approvals for TLX101-Px and Illuccix will accelerate commercialization timelines.
- Therapeutics Pipeline
- The pace at which TLX591-Tx and TLX250-Tx advance through pivotal trials could reshape Telix’s therapeutic portfolio.
- Capital Allocation
- How Telix balances R&D investment (US$230–270 million FY guidance) with manufacturing expansion and debt servicing.
Related topics